Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
PLoS Negl Trop Dis. 2012;6(7):e1735. doi: 10.1371/journal.pntd.0001735. Epub 2012 Jul 24.
Dengue is a mosquito-borne viral disease caused by four closely related serotypes of Dengue viruses (DENVs). This disease whose symptoms range from mild fever to potentially fatal haemorrhagic fever and hypovolemic shock, threatens nearly half the global population. There is neither a preventive vaccine nor an effective antiviral therapy against dengue disease. The difference between severe and mild disease appears to be dependent on the viral load. Early diagnosis may enable timely therapeutic intervention to blunt disease severity by reducing the viral load. Harnessing the therapeutic potential of RNA interference (RNAi) to attenuate DENV replication may offer one approach to dengue therapy.
METHODOLOGY/PRINCIPAL FINDINGS: We screened the non-translated regions (NTRs) of the RNA genomes of representative members of the four DENV serotypes for putative siRNA targets mapping to known transcription/translation regulatory elements. We identified a target site in the 5' NTR that maps to the 5' upstream AUG region, a highly conserved cis-acting element essential for viral replication. We used a replication-defective human adenovirus type 5 (AdV5) vector to deliver a short-hairpin RNA (shRNA) targeting this site into cells. We show that this shRNA matures to the cognate siRNA and is able to inhibit effectively antigen secretion, viral RNA replication and infectious virus production by all four DENV serotypes.
CONCLUSION/SIGNIFICANCE: The data demonstrate the feasibility of using AdV5-mediated delivery of shRNAs targeting conserved sites in the viral genome to achieve inhibition of all four DENV serotypes. This paves the way towards exploration of RNAi as a possible therapeutic strategy to curtail DENV infection.
登革热是一种由四种密切相关的登革病毒血清型(DENV)引起的蚊媒病毒性疾病。这种疾病的症状从轻度发热到潜在致命的出血热和低血容量性休克不等,威胁着近一半的全球人口。目前既没有预防疫苗,也没有针对登革热的有效抗病毒疗法。严重和轻度疾病之间的差异似乎取决于病毒载量。早期诊断可以通过降低病毒载量来及时进行治疗干预,从而减轻疾病的严重程度。利用 RNA 干扰(RNAi)的治疗潜力来减弱 DENV 复制可能是登革热治疗的一种方法。
方法/主要发现:我们在四种 DENV 血清型的 RNA 基因组的非翻译区(NTR)中筛选了可能映射到已知转录/翻译调节元件的 siRNA 靶标。我们在 5'NTR 中鉴定了一个靶位点,该位点映射到 5'上游 AUG 区域,这是一个高度保守的顺式作用元件,对病毒复制至关重要。我们使用复制缺陷型人腺病毒 5 型(AdV5)载体将靶向该位点的短发夹 RNA(shRNA)递送到细胞中。我们表明,这种 shRNA 成熟为相应的 siRNA,并能够有效抑制四种 DENV 血清型的抗原分泌、病毒 RNA 复制和感染性病毒产生。
结论/意义:这些数据证明了使用 AdV5 介导的递送靶向病毒基因组中保守位点的 shRNA 来抑制所有四种 DENV 血清型的可行性。这为探索 RNAi 作为一种可能的治疗策略来遏制 DENV 感染铺平了道路。